MX357759B - Formulaciones y formas de dosificacion de fosfolipidos oxidados. - Google Patents
Formulaciones y formas de dosificacion de fosfolipidos oxidados.Info
- Publication number
- MX357759B MX357759B MX2014002362A MX2014002362A MX357759B MX 357759 B MX357759 B MX 357759B MX 2014002362 A MX2014002362 A MX 2014002362A MX 2014002362 A MX2014002362 A MX 2014002362A MX 357759 B MX357759 B MX 357759B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- formulations
- dosage forms
- oxidized phospholipids
- capsules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Botany (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción provee composiciones farmacéuticas con un fosfolípido oxidado, tal como 1- hexadecil-2- (4´ -carboxibutil) -glicero-3-fosfocolina (VB-201) y un portador termoplástico, por ejemplo, a poloxámero. Las composiciones farmacéuticas además pueden comprender un agente anti-adherente, tal como talco y/o un agente tixotrópico. La presente descripción además provee procesos para preparar las composiciones farmacéuticas. La descripción además provee cápsulas con las composiciones farmacéuticas. Los usos de tales composiciones farmacéuticas y cápsulas en el tratamiento de trastornos inflamatorios también se describen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161529989P | 2011-09-01 | 2011-09-01 | |
PCT/US2012/053533 WO2013033642A1 (en) | 2011-09-01 | 2012-08-31 | Formulations and dosage forms of oxidized phospholipids |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014002362A MX2014002362A (es) | 2014-04-30 |
MX357759B true MX357759B (es) | 2018-07-24 |
Family
ID=46964020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014002362A MX357759B (es) | 2011-09-01 | 2012-08-31 | Formulaciones y formas de dosificacion de fosfolipidos oxidados. |
Country Status (16)
Country | Link |
---|---|
US (3) | US9254297B2 (es) |
EP (1) | EP2750668B1 (es) |
JP (1) | JP6109175B2 (es) |
KR (1) | KR101939430B1 (es) |
CN (1) | CN103874485B (es) |
AU (1) | AU2012301602B2 (es) |
BR (1) | BR112014004916B1 (es) |
CA (1) | CA2847218C (es) |
EA (1) | EA029274B1 (es) |
ES (1) | ES2768266T3 (es) |
HK (1) | HK1198430A1 (es) |
IL (1) | IL231222B (es) |
MX (1) | MX357759B (es) |
SG (1) | SG11201400208PA (es) |
WO (1) | WO2013033642A1 (es) |
ZA (1) | ZA201401478B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
EP2348864A4 (en) | 2008-10-08 | 2013-07-31 | Vascular Biogenics Ltd | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF |
JP5752599B2 (ja) | 2008-11-06 | 2015-07-22 | ヴァスキュラー バイオジェニックス リミテッド | 酸化脂質化合物およびその使用 |
EA029274B1 (ru) | 2011-09-01 | 2018-03-30 | Васкьюлар Байодженикс Лтд. | Препараты и лекарственные формы на основе окисленных фосфолипидов |
ES2855299T3 (es) | 2014-11-26 | 2021-09-23 | Vascular Biogenics Ltd | Lípidos oxidados y tratamiento o prevención de la fibrosis |
US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
US9540588B2 (en) * | 2014-12-16 | 2017-01-10 | Polymer Ventures Inc. | Oil recovery aid |
US10597603B2 (en) | 2014-12-16 | 2020-03-24 | Polymer Ventures, Inc. | Oil recovery aid |
JP6755530B2 (ja) * | 2016-09-02 | 2020-09-16 | 国立大学法人岩手大学 | 皮膚炎の予防又は治療用医薬組成物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
US4970233A (en) * | 1987-08-04 | 1990-11-13 | Mchugh John E | Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC) |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
US20030188756A1 (en) * | 2002-08-19 | 2003-10-09 | Cantorna Margherita T | Treatment of inflammatory bowel disease with vitamin d compounds |
JP4162486B2 (ja) | 2000-11-24 | 2008-10-08 | ヴァスキュラー バイオジェニックス リミテッド | アテローム性動脈硬化を防止および処置するための規定された酸化型リン脂質を用いる方法およびそのような酸化型リン脂質を含有する組成物 |
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
CN1501810A (zh) | 2001-01-04 | 2004-06-02 | 包含硬化斑相关分子的组合物和用于预防和治疗动脉粥样硬化的方法 | |
WO2004039308A2 (en) * | 2002-10-31 | 2004-05-13 | State Of Israel, Ministry Of Agriculture | Quinazolinone compositions for regulation of gene expression related to pathological processes |
US20060068015A1 (en) * | 2003-10-10 | 2006-03-30 | Per Holm | Solid dosage form comprising a fibrate and a statin |
US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
EP2574612A1 (en) | 2004-07-09 | 2013-04-03 | Vascular Biogenics Ltd. | Improved process for the preparation of oxidized phospholipids |
US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
EP2348864A4 (en) * | 2008-10-08 | 2013-07-31 | Vascular Biogenics Ltd | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF |
JP5752599B2 (ja) * | 2008-11-06 | 2015-07-22 | ヴァスキュラー バイオジェニックス リミテッド | 酸化脂質化合物およびその使用 |
JP2013516455A (ja) | 2010-01-05 | 2013-05-13 | バスキュラー バイオジェニックス リミテッド | Vb−201を用いた治療 |
EA029274B1 (ru) * | 2011-09-01 | 2018-03-30 | Васкьюлар Байодженикс Лтд. | Препараты и лекарственные формы на основе окисленных фосфолипидов |
-
2012
- 2012-08-31 EA EA201490544A patent/EA029274B1/ru not_active IP Right Cessation
- 2012-08-31 ES ES12766751T patent/ES2768266T3/es active Active
- 2012-08-31 WO PCT/US2012/053533 patent/WO2013033642A1/en active Application Filing
- 2012-08-31 SG SG11201400208PA patent/SG11201400208PA/en unknown
- 2012-08-31 MX MX2014002362A patent/MX357759B/es active IP Right Grant
- 2012-08-31 CN CN201280049926.9A patent/CN103874485B/zh active Active
- 2012-08-31 EP EP12766751.7A patent/EP2750668B1/en active Active
- 2012-08-31 KR KR1020147008443A patent/KR101939430B1/ko active IP Right Grant
- 2012-08-31 BR BR112014004916-5A patent/BR112014004916B1/pt not_active IP Right Cessation
- 2012-08-31 AU AU2012301602A patent/AU2012301602B2/en not_active Ceased
- 2012-08-31 JP JP2014528672A patent/JP6109175B2/ja active Active
- 2012-08-31 CA CA2847218A patent/CA2847218C/en active Active
-
2013
- 2013-03-11 US US13/792,633 patent/US9254297B2/en not_active Expired - Fee Related
-
2014
- 2014-02-26 ZA ZA2014/01478A patent/ZA201401478B/en unknown
- 2014-02-27 IL IL231222A patent/IL231222B/en active IP Right Grant
- 2014-11-26 HK HK14111949.3A patent/HK1198430A1/xx unknown
-
2016
- 2016-02-08 US US15/018,158 patent/US20160220590A1/en not_active Abandoned
-
2018
- 2018-06-08 US US16/003,173 patent/US20190008880A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA201401478B (en) | 2016-09-28 |
CA2847218C (en) | 2018-02-27 |
WO2013033642A1 (en) | 2013-03-07 |
AU2012301602B2 (en) | 2015-09-03 |
HK1198430A1 (en) | 2015-04-24 |
US20190008880A1 (en) | 2019-01-10 |
US20160220590A1 (en) | 2016-08-04 |
IL231222B (en) | 2018-01-31 |
MX2014002362A (es) | 2014-04-30 |
BR112014004916B1 (pt) | 2021-12-21 |
EP2750668A1 (en) | 2014-07-09 |
EA029274B1 (ru) | 2018-03-30 |
CA2847218A1 (en) | 2013-03-07 |
SG11201400208PA (en) | 2014-03-28 |
CN103874485B (zh) | 2017-06-09 |
US9254297B2 (en) | 2016-02-09 |
AU2012301602A1 (en) | 2013-05-02 |
KR101939430B1 (ko) | 2019-01-16 |
BR112014004916A2 (pt) | 2017-04-04 |
JP2014525463A (ja) | 2014-09-29 |
NZ621710A (en) | 2015-10-30 |
JP6109175B2 (ja) | 2017-04-05 |
EP2750668B1 (en) | 2019-12-11 |
US20130209555A1 (en) | 2013-08-15 |
IL231222A0 (en) | 2014-04-30 |
CN103874485A (zh) | 2014-06-18 |
KR20140078641A (ko) | 2014-06-25 |
EA201490544A1 (ru) | 2014-08-29 |
ES2768266T3 (es) | 2020-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX357759B (es) | Formulaciones y formas de dosificacion de fosfolipidos oxidados. | |
UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
PH12014501469A1 (en) | Bromodomain inhibitors | |
MX2013001677A (es) | Formulaciones estables de linaclotida. | |
MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
MX2015012006A (es) | Inhibidores de bromodominio tetraciclicos. | |
MX2010010647A (es) | Proceso para preparar formulaciones de dabigatran para administracion oral. | |
TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
MY168791A (en) | Carbamate compounds and of making and using same | |
MX2018012161A (es) | Lipidos y composiciones novedosas para el suministro de terapeuticos. | |
EP2576578A4 (en) | POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF | |
WO2012054500A3 (en) | Compositions for drug administration | |
TN2012000392A1 (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
IL222578A0 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
MX344787B (es) | Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. | |
MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
WO2013003827A3 (en) | Macrogol 15 hydroxystearate formulations | |
MX2015004604A (es) | Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas. | |
MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
IN2014DN06869A (es) | ||
WO2013040227A3 (en) | Therapeutic compounds | |
IN2014DN01619A (es) | ||
MX2014013664A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida. | |
WO2014064652A3 (en) | Stable pharmaceutical composition of peginterferon alpha-2b | |
MX2019012375A (es) | Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |